Radiotherapy of Pelvic Lymph Nodes in High Risk Prostate Cancer - A Retrospective Analysis
Radiotherapy of Pelvic Lymph Nodes in High Risk Prostate Cancer - A Retrospective Analysis
Men with high risk prostate cancer who underwent radiotherapy of the prostate/seminal
 vesicles or underwent postoperative radiotherapy including pelvic lymph nodes between 2010
 and 2016 are analyzed retrospectively. The aims are to estimate progression-free survival as
 well as toxicity according to CTCAE v4.03.
Collection of data and retrospective analysis of patients with high risk prostate cancer
 treated with radiotherapy to pelvic lymph nodes.

 What influence has irradiation of pelvic lymph nodes on patients with high risk prostate
 cancer in terms of progression free survival and toxicity. How does this influence side
 effects with respect to gastrointestinal (proctitis, abdominal pain, diarrhea) and
 genitourinary (cystitis, urinary disorders) toxicities (CTCAE v4.03)
Inclusion Criteria:

 -  Men with high risk prostate cancer treated with radiotherapy to prostate/seminal
 vesicles or postoperative radiotherapy and pelvic lymph nodes at the Kantonssptial
 Graubuenden, Department of Radiation Oncology between 2010 and 2016

 Exclusion Criteria:

 -  Men with prostate cancer other than high risk disease and no radiotherapy to pelvic
 lymph nodes